Philip Beer MRCP, FRCPath, PhD

ONCODNA S.A

Dr Philip Beer is a Physician Scientist and precision oncology specialist who operates across the commercial, academic and healthcare sectors. Philip holds diverse positions united by the singular goal of leveraging genomic technologies to improve outcomes for cancer patients, with a specific focus on the clinical implementation of cancer genomic platforms and the interpretation of the output data for use in routine oncology practice. Philip trained as a haematologist at Imperial College, London, followed by academic research at the University of Cambridge and the BC Cancer Agency, Vancouver. Current roles include work as a molecular and cellular pathologist at a flagship NHS diagnostic unit, clinical support for a leading commercial provider of cancer genomic analysis, translational support for early clinical stage oncology drug development in the pharmaceutical sector, and involvement in academic research projects encompassing cancer genomics and functional modelling.

dont miss

The evolution of oncology therapeutics in the genomic era.

Parallel advances in sequencing technology and synthetic chemistry have delivered a near-complete lexicon of genomic cancer drivers alongside the ability to target with therapeutic intent a diverse range of oncogenic molecules. Despite this progress, however, the impact of molecularly-targeted therapy has to date been relatively modest. Important barriers to the full realisation of the power of cancer genomics include the availability and reimbursement of genomic testing, access to suitably comprehensive testing, identification of biologically significant (‘driver’) mutations, and the reporting of complex genomic data in a clinically meaningful way. Perhaps most significant of all is a pressing need to re-evaluate approaches to clinical trial design and patient stratification in light of recent advances in our understanding of how cancers evolve to evade targeted and immune-based therapies.

EVEN MORE SEMINARS

  • Emlyn Samuel: Speaking at the Oncology Convention

    Emlyn Samuel
    Cancer Research UK

    Brexit: getting the best outcome for research and patients

  • Mohamed Torky: Speaking at the Oncology Convention

    Mohamed Torky
    Hospital Germans Trias i pujol. Barcelona. Spain

    Role of Radial-EBUS in diagnosis of lung cancer.

  • Philip Beer MRCP, FRCPath, PhD: Speaking at the Oncology Convention

    Philip Beer MRCP, FRCPath, PhD
    ONCODNA S.A

    The evolution of oncology therapeutics in the genomic era.

  • Mylaine Riobe MD, FABOIM, FACOG: Speaking at the Oncology Convention

    Mylaine Riobe MD, FABOIM, FACOG
    Riobe Institute of Integrative Medicine

    Cancer is not random! Evolving mechanisms for cancer causation and prevention

  • Michael Schreiber: Speaking at the Oncology Convention

    Michael Schreiber
    Brain Tumor Foundation, Chairman

    Brain Tumors - Innovation, support and advocacy